



EC Certificate

Full Quality Assurance System

Directive 98/79/EC on In Vitro Diagnostic Medical Devices (IVDD), Annex IV excluding (4, 6)
(List A and B and devices for self-testing)

No. V1 104507 0003 Rev. 06

Manufacturer:

ACON Laboratories, Inc.

5850 Oberlin Drive, #340
San Diego CA 92121
USA

**Product Category(ies): Blood glucose measuring systems for self testing
and self-testing devices for clinical chemistry,
hematology and pregnancy and ovulation**

The Certification Body of TÜV SÜD Product Service GmbH declares that the aforementioned manufacturer has implemented a quality assurance system for design, manufacture and final inspection of the respective devices / device families in accordance with IVDD Annex IV. This quality assurance system conforms to the requirements of this Directive and is subject to periodical surveillance. For marketing of List A devices an additional Annex IV (4) certificate is mandatory. All applicable requirements of the testing and certification regulation of TÜV SÜD Group have to be complied with. For details and certificate validity see: www.tuvsud.com/ps-cert?q=cert:V1_104507_0003_Rev.06

Report no.: SH22743EXT01

Valid from: 2022-05-04

Valid until: 2025-05-26

Date, 2022-05-04

Christoph Dicks
Head of Certification/Notified Body



EC Certificate

Full Quality Assurance System

Directive 98/79/EC on In Vitro Diagnostic Medical Devices (IVDD), Annex IV excluding (4, 6)
(List A and B and devices for self-testing)

No. V1 104507 0003 Rev. 06

Model(s):

On Call Plus Blood Glucose Monitoring System,
On Call Plus Blood Glucose Test Strips,
On Call EZ II Blood Glucose Monitoring System,
On Call Advanced Blood Glucose Monitoring System,
On Call Advanced Blood Glucose Test Strips,
On Call Chosen Blood Glucose Test Strips,
On Call Vivid Blood Glucose Monitoring System (OGM-101),
On Call Vivid Blood Glucose Test Strips (OGS-101),
On Call Sharp Blood Glucose Monitoring System (OGM-121),
On Call Sharp Blood Glucose Test Strips (OGS-121)
On Call Plus II Blood Glucose Monitoring System (OGM-171),
On Call Plus II Blood Glucose Test Strips (OGS-171),
On Call Extra Blood Glucose Monitoring System (OGM-191),
On Call Extra Blood Glucose Test Strips (OGS-191),
On Call GK Dual Blood Glucose & Ketone Monitoring System (OGM-161),
On Call Blood Ketone Test Strips (OGS-161),
Urinalysis Reagent Strips (Urine),
UTI Urinary Tract Infection Test Strips,
Cholesterol Monitoring System (CCM-111),
CHOL Total Cholesterol Test Devices (CCS-111),
TRIG Triglycerides Test Devices (CCS-112),
HDL High Density Lipoprotein Test Devices (CCS-113),
3-1 Lipid Panel Test Devices (CCS-114),
Cholesterol CTRL Control Devices,
Cholesterol Monitoring System (CCM-101),
CHOL Total Cholesterol Test Strips (CCS-101),
PT/INR Monitoring System (CCM-151),
PT/INR Test Strips (CCS-151),
Hemoglobin Testing System (CCM-141),
Hemoglobin Test Strips (CCS-141),
hCG Pregnancy Rapid Test Cassette (Urine),
Pregnancy Rapid Test Midstream,
On Call Extra Mobile Blood Glucose Monitoring System (OGM-281),
On Call Sure Blood Glucose Monitoring System (OGM-211),
On Call Sure Sync Blood Glucose Monitoring System (OGM-212),
On Call Sure Blood Glucose Test Strips (OGS-211),
GIMA Blood Glucose Monitoring System,
GIMA Bluetooth Blood Glucose Monitoring System,
GIMA Blood Glucose Test Strips,
On Call GU Dual Blood Glucose & Uric Acid Monitoring



EC Certificate

Full Quality Assurance System

Directive 98/79/EC on In Vitro Diagnostic Medical Devices (IVDD), Annex IV excluding (4, 6)
(List A and B and devices for self-testing)

No. V1 104507 0003 Rev. 06

System (OGM-201),
On Call Blood Uric Acid Test Strips (OGS-201),
LH Ovulation Rapid Test Cassette (Urine),
Ovulation Rapid Test Midstream,
Ovulation & Pregnancy Test Combo Pack,
On Call Extra Voice Blood Glucose Monitoring System
(OGM-291),
Early Detection Pregnancy Test,
Digital Pregnancy Test,
Go-Keto Blood Glucose & Ketone Monitoring System (OGM-
161),
Go-Keto Blood Ketone Test Strips (OGS-161),
Go-Keto Blood Glucose Test Strips,
On Call Extra GM Blood Glucose Monitoring System(OGM-
191),
On Call Extra GM Blood Glucose Test Strips (OGS-191),
On Call Plus GM Blood Glucose Monitoring System,
On Call Plus GM Blood Glucose Test Strips,
Go-Keto Urinalysis Reagent Strips

Facility(ies):

ACON Laboratories, Inc.
5850 Oberlin Drive, #340, San Diego CA 92121, USA

ACON Laboratories, Inc.
10125 Mesa Rim Road, San Diego CA 92121, USA

AZURE Institute, Inc.
10125 Mesa Rim Road, San Diego CA 92121, USA

Acon Laboratories Inc.
Guerrero Negro 9942 Parque Industrial Pacifico IV, 22644 Tijuana
B.C. CP, MEXICO



ACON Laboratories, Inc.

10125 Mesa Rim Road. · San Diego, CA 92121 · USA
Tel: (858) 875-8000 · Fax: (858) 875-8099 · E-mail: info@aconlabs.com

November 11th 2016

CERTIFICATION LETTER

This letter is to certify that, Vitalie Goreacii, employed by Sanmedico SRL located at: Republic of Moldova, city Chisinau, str. Petricani 88/1 of. 10, MD-2059, have received all required training and is enabled and authorized to provide services with installation, commissioning, and maintenance to the products listed below:

Mission® U120 Urine Analyzer
Mission® U120 Ultra Urine Analyzer
Mission® U500 Urine Analyzer
Mission® PT/INR Coagulation Monitoring System
Mission® Cholesterol Monitoring System
Mission® Ultra Cholesterol Monitoring System
Mission® HB Hemoglobin Testing System
Mission® Plus HB Hemoglobin Testing System
OnCall® Glucose Meter

For further questions or inquiries regarding this matter, please refer to the contact information below.

Sincerely

A handwritten signature in black ink, appearing to read "Jassy Alvarenga", is written over a red circular stamp.



Jassy Alvarenga
International Account Manager
ACON Laboratories, Inc. S.A.

jalvarenga@aconlabs.com

+1 858 875 8085

Declaration of Conformity

ACON Laboratories, Incorporated
5850 Oberlin Drive #340
San Diego, CA 92121, USA

**We, the manufacturer, declare under our sole responsibility that the
in vitro diagnostic device:**

Mission[®] Urinalysis Reagent Strips (U031-XX1)

classified as Others in the directive 98/79/EC,

**meets all the provisions of the directive 98/79/EC on *in vitro* diagnostic
medical devices which apply to it**

**The self-declaration is according to Annex III
(excluding Section 6) of the Directive.**

Authorized Representative:
Medical Device Safety Service GmbH
Schiffgraben 41
30175 Hannover, Germany

Signed this 11 day of February, 2020
in San Diego, CA USA



Qiyi Xie, MD, MPH
Senior Staff, Regulatory Affairs & Clinical Affairs
Acon Laboratories, Inc.



Declaration of Conformity

ACON Laboratories, Incorporated
5850 Oberlin Drive, #340
San Diego, CA 92121, USA

**We, the manufacturer, declare under our sole responsibility that the
in vitro diagnostic device:**

Device Name	REF Number	Model Number
Mission® Liquid Urine Control	U021-011	n/a
SPINREACT Liquid Urine Control	U021-013A	n/a
Insight® Liquid Urine Control	U021-015	n/a
Mission® Liquid Diptube Urine Control	U021-071	n/a
Insight® Liquid Diptube Urine Control	U021-075	n/a

classified as Others in the directive 98/79/EC,

**meets all the provisions of the directive 98/79/EC on *in vitro* diagnostic
medical devices which apply to it**

**The self-declaration is according to Annex III
(excluding Section 6) of the Directive.**

Authorized Representative:
Medical Device Safety Service GmbH
Schiffgraben 41
30175 Hannover, Germany

Signed this 22 day of October, 2021
in San Diego, CA, USA



Qiyi Xie, MD, MPH
Senior Staff, Regulatory Affairs & Clinical Affairs
Acon Laboratories, Inc.





Certificate

No. Q5 104507 0001 Rev. 03

Holder of Certificate: **ACON Laboratories, Inc.**
5850 Oberlin Drive, #340
San Diego CA 92121
USA

Certification Mark:



Scope of Certificate: **Design and Development, Manufacture and distribution of In Vitro Diagnostic Test Kits and Reagents for the Determination of Infectious Diseases, Clinical Chemistry, Drugs of Abuse, Tumor/Cardiac Marker, Fertility/Pregnancy and Blood Glucose Monitoring System, Lancing Devices and Lancets**

The Certification Body of TÜV SÜD Product Service GmbH certifies that the company mentioned above has established and is maintaining a quality management system, which meets the requirements of the listed standard(s). All applicable requirements of the testing and certification regulation of TÜV SÜD Group have to be complied with. For details and certificate validity see: [www.tuvsud.com/ps-cert?q=cert:Q5 104507 0001 Rev. 03](http://www.tuvsud.com/ps-cert?q=cert:Q5_104507_0001_Rev._03)

Report No.: SH22743A01

Valid from: 2022-09-15
Valid until: 2025-09-06

Date, 2022-09-15



Christoph Dicks
Head of Certification/Notified Body

Certificate

No. Q5 104507 0001 Rev. 03

Applied Standard(s):

EN ISO 13485:2016
Medical devices - Quality management systems -
Requirements for regulatory purposes
(ISO 13485:2016)
DIN EN ISO 13485:2016

Facility(ies):

ACON Laboratories, Inc.
5850 Oberlin Drive, #340, San Diego CA 92121, USA

Address holder for registration only

ACON Laboratories, Inc.
10125 Mesa Rim Road, San Diego CA 92121, USA

Manufacture and distribution of
In Vitro Diagnostic Test Kits and Reagents for the Determination of
Infectious Diseases, Clinical Chemistry, Drugs of Abuse,
Tumor/Cardiac Marker, Fertility/Pregnancy and Blood Glucose
Monitoring System, Lancing Devices and Lancets

ACON Laboratories, Inc.
6865 Flanders Dr., Suite B, San Diego CA 92121, USA

Storage of
In Vitro Diagnostic Test Kits and Reagents for the Determination of
Infectious Diseases, Clinical Chemistry, Drugs of Abuse,
Tumor/Cardiac Marker, Fertility/Pregnancy and Blood Glucose
Monitoring System, Lancing Devices and Lancets

AZURE Institute, Inc.
10125 Mesa Rim Road, San Diego CA 92121, USA

Design and Development of
In Vitro Diagnostic Test Kits and Reagents for the Determination of
Infectious Diseases, Clinical Chemistry, Drugs of Abuse,
Tumor/Cardiac Marker, Fertility/Pregnancy and Blood Glucose
Monitoring System, Lancing Devices and Lancets

Acon Laboratories Inc.
Guerrero Negro 9942 Parque Industrial Pacifico IV, 22644
Tijuana B.C. CP, MEXICO

Manufacture of
blood glucose test strips, antigen rapid test and IgG/IgM antibody
rapid test for infectious disease.



STATEMENT

We, ACON Laboratories, Inc., having a registered office at *5850 Oberlin Drive #340, San Diego, CA 92121* authorize SRL Sanmedico having a registered office at *A. Corobceanu street 7A, apt. 9, Chisinău, MD-2012, Moldova*

to register, notify, renew or modify the registration of medical devices on the territory of the Republic of Moldova.

Date: January 3, 2023

Signature:

A handwritten signature in black ink, appearing to read "Xie", is written over a horizontal line.

Qiyi Xie, Md, MPH
Sr. Officer, Regulatory & Clinical Affairs
ACON Laboratories, Inc.
Ph: 858-875-8011
Email: qxie@aconlabs.com

Mission® Urinalysis Reagent Strips and Urine Analyzers

Obtain reliable and cost-effective results with *Mission®* Urinalysis Reagent Strips and Urine Analyzers!

- *Accurate*
- *Reliable*
- *Convenient*



ACON®

Global Diagnostics for Local Markets™

Urinalysis Reagent Strips

Simple and Accurate



- Analytical sensitivity better than or comparable to market leaders
- High quality color chart ensures accurate visual reading

Flexible

- Compatible for visual and analyzer reading
- More than 30 different combinations available

Multiple Packaging Options and Long Shelf Life

- Canister Packaging
 - Available in 25, 50, 100 and 150 strips per kit
 - 2 year shelf life for unopened canisters which offers cost savings and convenience for high volume testing
 - 3 month shelf life for strips in opened canisters
- Pouch Packaging *New!*
 - Single-strip Pouch
 - Individually packaged strips with 1, 3, 6 and 20 strips and 1 color chart per kit for OTC or low volume testing
 - Unique packaging maintains 2 year shelf life for all strips in the kit compared to 3 months for remaining strips in an opened canister
 - Multi-strip Pouch
 - Canister Refill Kits with 25 strips/pouch uniquely packaged to save cost for low volume testing and extended shelf life by using the canister for refills



Step 1: Immerse strip into urine

Step 2: Remove excess urine

Step 3: Obtain results by analyzer or visual reading

Catalog No.	No. of Parameters	Type of Strip [♦]		Strips per Canister [◇]	Pouch Packaging [▲]	Reading Method			Analyzer-Read Strips: Standard (S) or Additional (A)	Parameters														
		For Visual Reading	For Analyzer Reading (U120/U500)			Visual	U120	U500		ASC	GLU	BIL	KET	SG	BLO	pH	PRO	URO	NIT	LEU	ALB	CRE		
U031-131	13	13C	NA	100*	✓	✓	NA	NA	A	*	*	*	*	*	*	*	*	*	*	*	*	*	*	
U031-111	11		11A	100	✓	✓	✓	✓	S	*	*	*	*	*	*	*	*	*	*	*	*	*	*	
U031-101	10		10U	100	✓	✓	✓	✓	S		*	*	*	*	*	*	*	*	*	*	*	*	*	
			10A			✓	✓	✓	A	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
			10C			✓	✓	✓	S		*	*	*	*	*	*	*	*	*	*	*	*	*	*
U031-091	9		9U	100	✓	✓	✓	✓	S		*	*	*	*	*	*	*	*	*	*	*	*	*	
U031-081	8		8U	100	✓	✓	✓	✓	A		*	*	*	*	*	*	*	*	*	*	*	*	*	
			8N			✓	✓	✓	S	*	*	*	*	*	*	*	*	*	*	*	*	*	*	
			8S			✓	✓	✓	A	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
U031-071	7		7N	100	✓	✓	✓	✓	A		*	*	*	*	*	*	*	*	*	*	*	*	*	
U031-061	6	6N	6NE	100	✓	✓	✓	✓	A		*	*	*	*	*	*	*	*	*	*	*	*	*	
		6U	6UE			✓	✓	✓			*	*	*	*	*	*	*	*	*	*	*	*	*	*
U031-051	5	5B	5BE	100	✓	✓	✓	✓	A		*	*	*	*	*	*	*	*	*	*	*	*	*	
		5N	5NE			✓	✓	✓			*	*	*	*	*	*	*	*	*	*	*	*	*	
		5S	5SE			✓	✓	✓			*	*	*	*	*	*	*	*	*	*	*	*	*	*
		5U	5UE			✓	✓	✓			*	*	*	*	*	*	*	*	*	*	*	*	*	*
U031-041	4	4S	4SE	100	✓	✓	✓	✓	A		*	*	*	*	*	*	*	*	*	*	*	*	*	
		4B	4BE			✓	✓	✓			*	*	*	*	*	*	*	*	*	*	*	*	*	
		4K	4KE			✓	✓	✓			*	*	*	*	*	*	*	*	*	*	*	*	*	*
		4G	4GE			✓	✓	✓			*	*	*	*	*	*	*	*	*	*	*	*	*	*
		4N	4NE			✓	✓	✓			*	*	*	*	*	*	*	*	*	*	*	*	*	*
		4P	4PE			✓	✓	✓			*	*	*	*	*	*	*	*	*	*	*	*	*	*
U031-031	3	3P	3PE	100	✓	✓	✓	✓	A		*	*	*	*	*	*	*	*	*	*	*	*	*	
		3K	3KE			✓	✓	✓			*	*	*	*	*	*	*	*	*	*	*	*		
		3G	3GE			✓	✓	✓			*	*	*	*	*	*	*	*	*	*	*	*		
		3N	3NE			✓	✓	✓			*	*	*	*	*	*	*	*	*	*	*	*		
U031-021	2	2G	2GE	100	✓	✓	✓	✓	A		*	*	*	*	*	*	*	*	*	*	*	*		
		2K	2KE			✓	✓	✓			*	*	*	*	*	*	*	*	*	*	*			
		2N	2NE			✓	✓	✓			*	*	*	*	*	*	*	*	*	*	*			
		2B	2BE			✓	✓	✓			*	*	*	*	*	*	*	*	*	*	*			
		2U	2UE			✓	✓	✓			*	*	*	*	*	*	*	*	*	*	*			
		2S	2SE			✓	✓	✓			*	*	*	*	*	*	*	*	*	*	*			
		2C	2CE			✓	✓	✓			*	*	*	*	*	*	*	*	*	*				
U031-011	1	1B	1BE	100	✓	✓	✓	✓	A					*										
		1P	1PE			✓	✓	✓						*										
		1G	1GE			✓	✓	✓			*													
		1K	1KE			✓	✓	✓				*												
		1R	1RE			✓	✓	✓						*										

♦Type of Strip:
 Visual Strip Size
 1-6 Parameters: 5 mm x 80 mm; 7-11 Parameters: 5 mm x 108 mm;
 12-13 Parameters: 5 mm x 121 mm
 U120/U500 Strip Size
 1-11 Parameters: 5 mm x 108 mm;
 "E" means extended strip length for 1-6 Parameters

◇ Also available in canisters of 25, 50 and 150 strips
 * Not available in canisters of 150 strips
 ▲ Single-strip Pouch available in 1, 3, 6 and 20 strip kit
 Canister Refill Kit, with 25 strips per pouch or canister, available in 3-pouch and 1- canister kit, or 4-pouch kit



U120 Urine Analyzer



Accurate

- Up to 120 tests/hour in Continuous Test Option
- Capable of reading 1 strip at a time in Single Test Option
- Test modes include Routine, STAT and QC
- Automatic calibration for accurate results and easy operation

Reliable

- Can read up to 4 Strip combinations with 8, 9, 10, 11 parameters, additional strips with 1-11 parameters available upon request
- Minimal training required

Convenient Operation

- Saves and recalls the last 2,000 results automatically
- Audible beep signals operator to dip strips in urine
- Can print up to 3 copies per test for convenient reviewing and easy record keeping
- Option to print results on sticker paper for quick and simple record management

Easy Data Management

- Includes RS232C port for easy data transfer to an external computer or LIS
- Optional Barcode Reader to record patient ID

Unique Lockout Functions *new!*

- Strip Lockout
 - Prevents using strips of another brand on the U120 Urine Analyzer
 - Requires barcode reader scan or manual entry of the canister code
- User Lockout
 - Eliminates unapproved users from testing
 - Up to 10 lab operators can perform testing, but only the lab administrator can change analyzer settings
- QC Lockout
 - Prevents testing without passing QC
 - QC tests can be performed once every 8 hours, day, week or month
 - Analyzer will alert when to run QC test
 - If QC tests fail, analyzer will switch to STAT mode and list "E" at the end of each test number

Specifications

Feature	Specifications
Analyzer Type	Manual
Methodology	Reflectance Photometry
Detection	Photosensitive Diode
Throughput	Single Test Option: 60 tests/hour Continuous Test Option: 120 tests/hour
Test Modes	Routine, STAT and QC
Lockout Functions	Strip Lockout: Available Upon Request; User/QC Lockout: Included with option to turn ON/OFF
Memory	Last 2,000 results
Strip Incubation Time	1 Minute
Wavelength of Monochromatic LED	525 nm and 635 nm
Standard Strips	8, 9, 10, 11 Parameters (5 mm x 108 mm)
Additional Strips Available	1-11 Parameters (5 mm x 108 mm); see URS Parameters
Total Combinations Per Analyzer	4 Combinations
Analyzer Ports	Standard RS232C Port for Barcode Reader or Data Transfer USB Port for Data Transfer 25 Pin Parallel Port for External Printer
Capabilities	Internal Thermal Printer (included) RS232C Barcode Reader (optional) Optional External Printer (not included) USB or RS232C Data Transfer Cable (optional)
Major Readable Barcodes	Code 128, Code 39, Codabar (NW-7), Interleaved 25, UPC-A, UPC-E, EAN 8, EAN 13
Calibration	Automatic
Available Languages on the Screen	English and additional language(s)
Operating Conditions	0-40°C (32-104°F); ≤ 85% RH
Storage Conditions	-5-50°C (23-122°F); ≤ 90% RH
Power Source	100-240 VAC, 50-60 Hz
Dimensions (L x W x H)	27.2 cm x 26.9 cm x 14.6 cm (10.7" x 10.6" x 5.7")
Display Dimensions (L x W)	10.8 cm x 5.7 cm (4.2" x 2.2")
Weight	2.6 kg (5.7 lbs)

Ordering Information

Product Name	Catalog No.	Components	Kit Box Dimensions (L x W x H) & Weight	Carton Dimensions (L x W x H) & Weight	Number of Kits/Carton
U120 Urine Analyzer	U111-101 [†]	1 Urine Analyzer 1 Strip holder 2 Printer Paper Rolls	2 Fuses (2.0A) 1 Power Cord 1 Quick Start Guide 1 Instruction Manual	42.0 cm x 41.5 cm x 31 cm; 5.0 kg 16.4" x 16.2" x 12.1"; 176.4 oz	1
U120 Urine Analyzer with Barcode Reader	U111-111 [†]	1 Urine Analyzer 1 Strip holder 2 Printer Paper Rolls 1 Barcode Reader (RS232C)	2 Fuses (2.0A) 1 Power Cord 1 Serial Splitter Cable (RS232C) 1 Quick Start Guide 1 Instruction Manual	44.5 cm x 44.5 cm x 40.0 cm; 5.5 kg 17.5" x 17.5" x 15.7"; 194 oz	1
Barcode Reader	U221-111 [†]	1 Barcode Reader (RS232C)	1 Serial Splitter Cable (RS232C)	23.6 cm x 10.8 cm x 7.8 cm; 0.482 kg 9.3" x 4.3" x 3.1"; 17.0 oz 63.0 cm x 37.0 cm x 30.0 cm; 12.0 kg 24.8" x 14.6" x 11.8"; 423.3 oz	22
Printer Paper Rolls	U121-101	4 Printer Paper Rolls	Thermal Paper (0.06 m x 20 m): 200 results/roll Sticker Paper (0.06 m x 9 m): 100 results/roll	12.0 cm x 12.0 cm x 6.5 cm; 0.36 kg 4.7" x 4.7" x 2.6"; 12.7 oz 63.0 cm x 37.0 cm x 30.0 cm; 21.4 kg 24.8" x 14.6" x 11.8"; 684.3 oz 12.0 cm x 12.0 cm x 6.5 cm; 0.4 kg 4.7" x 4.7" x 2.6"; 14.1 oz 24.8" x 14.6" x 11.8"; 684.3 oz; 754.9 oz	50
U120 Data Transfer Kit	U221-131 [†]	1 Data Transfer Cable (RS232C)	1 Package Insert	16.0 cm x 13.0 cm x 3.5 cm; 0.147 kg 6.3" x 5.1" x 1.4"; 5.2 oz 25.0 cm x 21.0 cm x 15.0 cm; 1.36 kg 9.8" x 8.3" x 5.9"; 48.0 oz	8

✓ CE Marked for sale in the European Community **CE**
 † Cleared for US 510(k)

U500 Urine Analyzer



Accurate and Efficient

- Up to 500 tests/hour for medium/large volume sample testing
- Professional accuracy equivalent to market leader
- Automatic strip detection and alignment for better efficiency
- Test modes include Routine, STAT and QC

Easy to Operate

- Large touch screen LCD offers simple menu navigation
- Uniquely designed strip platform/waste tray unit for easy one-step cleaning

Convenient

- Automatic calibration and waste disposal reduce hands-on time
- Can read strips with 8, 9, 10, 11 parameters, additional strips with 1-11 parameters available upon request
- Strip selection of up to 4 combinations for analyzer reading
- Stores up to 2,000 records and automatically flags abnormal results
- Capable of printing results on sticker paper for quick and easy record management

Data Management Capability

- Includes RS232C port for easy data transfer to an external computer or LIS
- Optional Barcode Reader to record patient ID

Unique Lockout Functions Coming Soon!

- Strip Lockout
 - Prevents using strips of another brand on the U500 Urine Analyzer
 - Requires barcode reader scan or manual entry of the canister code
- User Lockout
 - Eliminates unapproved users from testing
 - Up to 10 lab operators can perform testing, but only the lab administrator can change analyzer settings
- QC Lockout
 - Prevents testing without passing QC
 - QC tests can be performed once every 8 hours, day, week or month
 - Analyzer will alert when to run QC test
 - If QC tests fail, analyzer will switch to STAT mode and list "E" at the end of each test number

Specifications

Feature	Specifications
Analyzer Type	Semi-Automatic
Methodology	Reflectance Photometry
Detection	Photosensitive Diode
Throughput	500 tests/hour (Measuring cycle: 7 seconds/test)
Test Modes	Routine, STAT and QC
Lockout Functions	Strip Lockout: Available Upon Request; User/QC Lockout: Included with option to turn ON/OFF
Memory	Last 2,000 Records
Strip Incubation Time	1 Minute
Wavelength	525 and 635 nm
Standard Strips	8, 9, 10, 11 Parameters (5 mm x 108 mm)
Additional Strips Available	1-11 Parameters (5 mm x 108 mm); see URS Parameters
Total Combinations Per Analyzer	4 Combinations
Waste Disposal Capacity	Up to 150 Strips
Analyzer Ports	Standard RS232C Port for Barcode Reader or Data Transfer 25 Pin Parallel Port for External Printer
Capabilities	Internal Thermal Printer (included) RS232C Barcode Reader (optional) Optional External Printer (not included) RS232C Data Transfer Cable (optional)
Major Readable Barcodes	Code 128, Code 39, Codabar (NW-7), Interleaved 25, UPC-A, UPC-E, EAN 8, EAN 13
Calibration	Automatic
Available Languages on the Screen	English and additional language(s)
Operating Conditions	0-40°C (32-104°F); ≤85% RH
Storage Conditions	-5-50°C (23-122°F); ≤90% RH
Power Source	100-240 VAC, 50-60 Hz
Dimensions (L x W x H)	36.6 cm x 28.3 cm x 19.5cm (14.4" x 11.1" x 7.7")
Display Dimensions (L x W)	11.5 cm x 9.0 cm (4.5" x 3.5")
Weight	4.0 kg (8.8 lbs)

Ordering Information

Product Name	Catalog No.	Components	Kit Box Dimensions (L x W x H) & Weight	Carton Dimensions (L x W x H) & Weight	Number of Kits/Carton
U500 Urine Analyzer	U211-101 [✓]	1 Urine Analyzer 1 Strip Platform/Waste Tray 2 Printer Paper Rolls	2 Fuses (2.0A) 1 Power Cord 1 Instruction Manual	51.0 cm x 42.0 cm x 38.5 cm; 7 kg 20.1" x 16.5" x 15.2"; 246.9 oz	1
U500 Urine Analyzer with Barcode Reader	U211-111 [✓]	1 Urine Analyzer 1 Strip Platform/Waste Tray 2 Printer Paper Rolls 1 Barcode Reader (RS232C)	2 Fuses (2.0A) 1 Power Cord 1 Serial Splitter Cable (RS232C) 1 Instruction Manual	55.0 cm x 55.0 cm x 55.0cm; 9.2 kg 21.7" x 21.7" x 21.7"; 324.5 oz	1
Barcode Reader	U221-111 ^{✓†}	1 Barcode Reader (RS232C)	1 Serial Splitter Cable (RS232C)	23.6 cm x 10.8 cm x 7.8 cm; 0.482 kg 9.3" x 4.3" x 3.1"; 17.0 oz	22
Printer Paper Rolls	U121-101	4 Printer Paper Rolls	Thermal Paper (0.06 m x 20 m): 200 results/roll Sticker Paper (0.06 m x 9 m): 100 results/roll	12.0 cm x 12.0 cm x 6.5 cm; 0.360 kg 4.7" x 4.7" x 2.6"; 12.7oz 63.0 cm x 37.0 cm x 30.0 cm; 19.4 kg 24.8" x 14.6" x 11.8"; 684.3 oz 12.0 cm x 12.0 cm x 6.5 cm; 0.40 kg 4.7" x 4.7" x 2.6"; 14.1oz 63.0 cm x 37.0 cm x 30.0 cm; 21.4 kg 24.8" x 14.6" x 11.8"; 684.3 oz; 754.9 oz	50
U500 Data Transfer Kit	U221-131 [✓]	1 Data Transfer Cable (RS232C)	1 Package Insert	16.0 cm x 13.0 cm x 3.5 cm; 0.147kg 6.3" x 5.1" x 1.4"; 5.2 oz	8

We also offer other rapid diagnostic and medical products:

Blood Glucose Monitoring Systems, Immunoassay EIA/ELISA and more.

✓ CE Marked for sale in the European Community **CE**
† Cleared for US 510(k)



Declaration Ref No: DC22-0065

CE Declaration of Conformity

According to Annex III of the IVD Directive 98/79/EC

We,

Atlas Medical GmbH

Head office: Ludwig-Erhard-Ring 3
Blankenfelde-Mahlow, Germany.

Tel: +49 - 33708 – 3550 30

Email: info@atlas-medical.com

Manufacturing Site: Sahab Free Zone Area, P. O. Box 204, Amman 11512, Jordan.

Tel.: +962 6 4026468

Fax: +962 6 4022588

Email: info@atlas-medical.com

Declare our responsibility that the following product:

See Attached list


- Comply with all essential requirements (Annex I) of the IVD Directive 98/79/EC. This compliance has been properly documented and covers the items listed in Annex I of the IVD Directive.
- This product is produced under Atlas quality system (ISO13485:2016) issued by GMED:
Certificate N^o.: 36655 rev 1
Expiry Date: October 8th.2023
- Comply with the essential requirements of following standards (EN 18113-1, -2,-4:2011, EN ISO 15223:2016 , EN ISO 23640:2015, EN ISO 14971:2019, ISO 2859/1:1999, EN ISO 13612:2002, EN ISO 13641:2002.

And

Intended for In-Vitro Professional use only.

Manufacturer
Atlas Medical
Ludwig-Erhard-Ring 3
Blankenfelde-Mahlow , Germany.



Atlas Medical	Issue date	Date of review	Management approval	MRXDO10F.10 08.02.2011
	May.2022	21.05.2022		

CE Declaration of Conformity

According to Annex III of the IVD Directive 98/79/EC

Item code	Product Description
8.00.01.0.0100	Atlas CRP Latex Kit with Buffer (100 Tests)
8.00.05.0.0100	Atlas RF Latex kit with Buffer(100 Tests)
8.00.11.0.0050	Atlas SLE Latex kit (50 Tests)
8.00.11.0.0100	Atlas SLE Latex kit (100 Tests)
8.00.12.0.0100	Atlas Staphylococcus Latex Kit (100 Tests)
8.00.17.0.0050	Atlas D-Dimer Latex Kit (50 Tests)
8.00.19.3.0100	Atlas TPHA Kit (100 Tests)
8.00.19.3.0200	Atlas TPHA Kit (200 Tests)
8.00.20.3.2500	Atlas VDRL Kit, 5ml+55ml buffer
8.04.38.0.0020	Atlas Fecal Occult Blood Test (FOB) Test Cassette , 20 Tests/Box
8.04.85.0.0050	Atlas Fecal Occult Blood Test (FOB) Test Strip, 50 Tests/Box
8.04.109.0.0020	Atlas Procalcitonin test (PCT) , 20 Tests/Box
8.16.78.0.0025	Atlas Calprotectin Test Cassette , 25 Tests/Box
8.04.45.0.0001	Atlas Troponin I Test Cassette, Bulk
8.04.45.0.0020	Atlas Troponin I Test Cassette , 20 Tests/Box.
8.04.45.0.0030	Atlas Troponin I Test Cassette , 30 Tests/Box.
8.04.46.0.0001	Atlas Myoglobin Test Cassette, Bulk
8.04.46.0.0020	Atlas Myoglobin Test Cassette , 20 Tests/Box.
8.04.46.0.0030	Atlas Myoglobin Test Cassette , 30 Tests/Box.
8.04.47.0.0001	Atlas CK-MB Test Cassette , Bulk.
8.04.47.0.0020	Atlas CK-MB Test Cassette , 20 Tests/Box.
8.04.47.0.0030	Atlas CK-MB Test Cassette , 30 Tests/Box.
8.04.48.0.0001	Atlas Cardiac Triple Tests Cassette (Troponin I, CK-MB, Myoglobin), Bulk.
8.04.48.0.0020	Atlas Cardiac Triple Tests Cassette (Troponin I, CK-MB, Myoglobin), 20 Tests/Box.
8.04.48.0.0030	Atlas Cardiac Triple Tests Cassette (Troponin I, CK-MB, Myoglobin), 30 Tests/Box.
8.14.19.1.0096	Helicobacter pylori Antigen ELISA, 96 Tests.
8.51.00.0.0096	25-OH VITAMIN D Elisa Kit, 96 Tests.
8.57.00.0.0096	Vitamin B12 Elisa Kit, 96 Tests



Date: 05/Jan/2023

STATEMENT


We, Atlas Medical having a registered office at Ludwig-Erhard-Ring 3, 15827 Blankenfelde-Mahlow, Berlin, Germany assign SRL Sanmedico having a registered office at A. Corobceanu Street 7A, apt.9, Chisinau MD-2012, Moldova, as authorized representative in correspondence with the conditions of directive 98/79/EEC.

We declare that the company mentioned above is authorized to register, notify, renew or modify the registration of medical devices on the territory of the Republic of Moldova.

On Behalf of Manufacturer:

General Manager

Haya Amawi

Signature: 

Date: 05.01.2023

Atlas Medical GmbH
Ludwig - Erhard Ring 3
15827 Blankenfelde - Mahlow
Tel. (0049) 33708 - 355030

Atlas Medical: Ludwig-Erhard-Ring 3, 15827 Blankenfelde-Mahlow, Berlin, Germany,
Tel:+4933708355030

Regulatory Office: William James House, Cowley Rd, Cambridge, CB4 0WX, United Kingdom
Tel: +44 (0) 1223 858 910

Middle East Site: P.O Box 204, King Abdullah II Industrial Estate, Amman, 11512, Jordan
Tel: +962 6 4026468

GMED certifie que le système de management de la qualité développé par
GMED certifies that the quality management system developed by

ATLAS MEDICAL GmbH
Ludwig-Erhard-Ring 3
15827 Blankenfelde-Mahlow GERMANY

pour les activités
for the activities

Conception et développement, fabrication et vente de dispositifs médicaux de diagnostic in vitro .

Design and Development, Manufacturing and Sales of in vitro diagnostic medical devices.

réalisées sur le(s) site(s) de
performed on the location(s) of

Voir addendum
See addendum

est conforme aux exigences des normes internationales
complies with the requirements of the international standards

ISO 13485: 2016

Début de validité / Effective date October 9th, 2023 (included)

Valable jusqu'au / Expiry date : October 8th, 2026 (included)

Etabli le / Issued on : October 9th, 2023




CERTIFICATION DE SYSTEMES DE MANAGEMENT
Accréditation n°4-0608
Liste des sites accrédités
et portée disponible sur
www.cofrac.fr

GMED N° 36655-2

Ce certificat est délivré selon les règles de certification GMED / This certificate is issued according to the rules of GMED certification

Renouvelle le certificat 36655-1



On behalf of the President
Béatrice LYS
Technical Director

Ce certificat couvre les activités et les sites suivants :
This certificate covers the following activities and sites:

French version :

Conception et développement, fabrication et vente de dispositifs médicaux de diagnostic *in vitro* à usage professionnel et/ ou d'autodiagnostic, dans les domaines du groupage sanguin, de la microbiologie, de la biochimie, de la toxicologie, de l'oncologie, de la cardiologie, de l'histologie, de l'endocrinologie et des maladies infectieuses, dans les techniques d'Agglutination/ ELISA/ Tests rapides/ Colorimétrie/ Disques antibiotiques.

English version:

Design and Development, Manufacturing and Sales of in vitro diagnostic medical devices for professional use and/or for self-testing, in the field of Immunohematology, Microbiology, Biochemistry, Toxicology, Oncology, Cardiology, Histology, Endocrinology Biosensors and Infectious diseases, in techniques of Agglutination/ ELISA/ Rapid tests/ Colorimetry/Antibiotic disks.

**ATLAS MEDICAL GmbH
Ludwig-Erhard-Ring 3
15827 Blankenfelde-Mahlow
GERMANY**

French version:

Siège social, responsable de la mise sur le marché

English version:

Headquarter, legal manufacturer

**Sahab Industrial Zone Area
King Abdullah II Industrial City
Amman 11512
JORDAN**


French version:

Conception, fabrication et contrôle final

English version:

Design, manufacture and final control

2 sites / 2 sites

DocuSigned by:
Beatrice Lys
FF33BDA8...AA04A3...


**On behalf of the President
Béatrice LYS
Technical Director**

ATLAS SLE SLIDE TEST

IVD For *in vitro* diagnostic and professional use only

2°C  8°C
Store at 2°-8°C

INTENDED USE

Atlas SLE Slide Test is a slide agglutination assay for the qualitative and semi quantitative detection of anti-deoxyribonucleoprotein (anti-DNP) in human serum. No initial dilution of patient samples is required for this test. These materials are intended to be acquired, possessed and used only by health professionals.

INTRODUCTION

The detection of antinuclear antibodies, by such laboratory methods as immunofluorescence, LE cell test, and agglutination of coated particles, can aid in the diagnosis of such autoimmune diseases as systemic lupus erythematosus (SLE). The antibodies most associated with SLE are those directed against DNP. These antibodies are believed to cause the formation of the LE cell *in vitro*, occurring in 75-80% of patients diagnosed as having SLE. Given that 20-25% of SLE patients do not exhibit the formation of LE cells, other methods can be used to detect antinuclear antibodies.

PRINCIPLE

Atlas SLE Slide Test provides a means of detecting anti-DNP in human serum. SLE Slide reagent is a stabilized buffered suspension of polystyrene latex particles that have been coated with DNP. When the latex reagent is mixed with the serum containing antibodies to DNP, agglutination occurs. Using dilutions of a reactive patient sample, the anti-DNP titer can be determined.

MATERIALS

MATERIALS PROVIDED

- SLE Latex Reagent: Suspended inert latex particles coated with DNP, with 0.1% sodium azide as preservative.
- SLE Positive Human serum or defibrinated plasma (liquid), with 0.1% sodium azide as preservative.

- SLE Negative Control: Non-reactive buffer containing BSA and 0.1% sodium azide.
- Stirring sticks.
- Glass slide.
- Package insert.

MATERIALS NEEDED BUT NOT PROVIDED

- Timing device.
- 13 x 75 mm test tubes
- Volumetric pipet to deliver 0.25 ml
- Saline (0.9% NaCl solution)
- Mechanical rotator (optional)

PACKAGING CONTENTS

REF 8.00.11.0.0025 (1x1 mL Latex, 1x0.5 mL Positive Control, 1x0.5 mL Negative Control)

REF 8.00.11.0.0050 (1x2 mL Latex, 1x0.5 mL Positive Control, 1x0.5 mL Negative Control)

REF 8.00.11.0.0100 (1x4 mL Latex, 1x1 mL Positive Control, 1x1 mL Negative Control)

PRECAUTIONS

- For *in vitro* diagnostic use.
- Latex reagent and controls contain sodium azide. Azides in contact with lead and copper plumbing may react to form highly explosive metal azides. When disposing of reagents containing azide, flush down the drain with large quantities of water to prevent azide build-up.
- The controls contain human serum or plasma which has been tested at the donor level for HBsAg and for HIV-1, HIV-2 and HCV antibodies and found to be nonreactive. As no known test offers complete assurance that infectious agents are absent, the controls should be considered potentially infectious and universal precautions should be used.
- Do not pipet by mouth.
- Do not smoke, eat, drink or apply cosmetics in areas where plasma/serum samples are handled.
- Any cuts, abrasions or other skin lesions should be suitably protected.
- In order to obtain reliable and consistent results, the instructions in the package insert must be strictly followed.
- Do not modify the handling and storage conditions for reagents or samples.
- Do not use past the expiration date indicated on the kit.
- Do not interchange components of one kit with those of another kit.

- Turbidity or precipitation in controls is indicative of deterioration and the component should not be used.
- Bacterial contamination of reagents or specimens may cause false positive results.

STORAGE & STABILITY

- Store all reagents at 2-8°C in an upright position when not in use.
- Do not freeze reagents.

SPECIMEN COLLECTION and STORAGE

- Use only serum that is free from contamination. Test samples should not be heat-inactivated.
- It is preferable to test samples on the day of their collection. If samples cannot be tested immediately, maintain them in their original tubes at 2-8°C and test within 48 hours.
- Serum samples stored longer than 48 hours should be stored at -20°C or below until testing. Avoid repeated freezing and thawing of specimens.
- If necessary before testing, centrifuge the specimens at a force sufficient to sediment cellular components.
- Samples to be sent out for testing should be placed on ice packs and packaged like any other biohazardous material that could potentially transmit infection.

REAGENT PREPARATION

- Allow all reagents and samples to warm to room temperature (20-30°C) before use. Do not heat reagents in a water bath.
- All reagents are ready for use as supplied. Gently mix the reagents before use; avoid foaming.
- Gently mix the latex reagent before each use to ensure homogeneity.

PROCEDURES

A. Method I (Qualitative)

1. Dispense (35 µL) of each serum sample onto a separate circle on the test slide. Add one drop of Positive and negative controls from the dropper vials supplied onto a separate circle on the test slide.
2. Dispense one drop of latex reagent (35 µL) to each serum specimen and to each control.
3. Using the flat end of the stirring sticks, mix each specimen and control serum with the latex reagent, in a circular manner, over the entire area in the circles of the card.

- Gently tilt and rotate the card for one (1) minute and observe for agglutination. All test results should be compared to both positive and negative controls.

INTERPRETATION OF RESULTS (QUALITATIVE)

Agglutination indicates a reactive SLE sample. Sera that elicit a reactive result should be retested and tittered using the "Semi quantitative Assay Protocol".

B. Method II (Semi-Quantitative)

- Prepare serial dilutions of patient serum, in saline, in test tubes as follows:

Tube	Dilution	Composition
1	1:2	0.25 ml of serum + 0.25 ml saline.
2	1:4	0.25 ml from tube 1 + 0.25 ml saline.
3	1:8	0.25 ml from tube 2 + 0.25 ml saline.
4	1:16	0.25 ml from tube 3 + 0.25 ml saline.
5	1:32	0.25 ml from tube 4 + 0.25 ml saline.
6	1:64	0.25 ml from tube 5 + 0.25 ml saline.

Note: Testing on additional dilutions should be performed as needed.

- Using each dilution as a separate test specimen, apply the samples to the slide as described in Step 1 of the "Qualitative method" and proceed with Steps 2 through 4 of the "Qualitative method". Include undiluted sample if not tested previously on that day with the same lot of latex reagent.

INTERPRETATION OF RESULTS (SEMI-QUANTITATIVE)

The highest dilution in which visible agglutination occurs is considered the endpoint titer.

QUALITY CONTROL

Quality Control requirements must be performed in accordance with applicable local, state and/or federal regulations or accreditation requirements and your laboratory's standard Quality Control Procedures. Controls with graded reactivity should be included. If control samples do not yield the expected response, the assay should be considered invalid and the assay repeated. If the repeat assay does not elicit the expected results for the control samples, discontinue use of the kit and contact your local distributor.

EXPECTED VALUES

Serum samples from 155 individuals were tested using the **SLE Slide Test**. Of the 155 individuals, 29 had active SLE, 23 had clinically inactive SLE, 8 had connective tissue diseases and the remaining 95 were either clinically normal or had some nonrelated disease (including anemia, infectious mononucleosis and rheumatic heart disease) and were used

as controls. Results from testing with the **SLE Slide Test** were compared with the results from testing of the samples using a standard LE cell preparation assay and a fluorescent ANA assay.

Of the 29 active SLE patients, 82% were positive using the SLE Slide Test, 86% were positive by the LE cell prep, and 82% positive by the ANA test. For the 23 clinically inactive SLE patients, 19% were positive by both the SLE Slide Test and the LE cell prep; and 71% were positive by the ANA test. None of the 8 patients having connective tissue disease tested positive with the SLE Latex Test, whereas 17% and 50% tested positive by the LE cell prep and the ANA procedures, respectively. Of the controls, 1% tested positive by both the SLE Latex Test and the LE cell prep, while 6% tested positive by the ANA assay.

LIMITATION

- Serum from patients with scleroderma, rheumatoid arthritis, dermatomyositis, and a variety of connective tissue diseases may elicit agglutination in the SLE slide test.
- Because extremely high levels of antibodies might affect the degree of agglutination, positive samples should be reassayed using the semi quantitative procedure.
- Contaminated, lipemic, or grossly hemolyzed sera should not be used because of the possibility of nonspecific results.
- Plasma samples should not be used because of the possibility of nonspecific results.
- Samples yielding indeterminate results may be resolved by repeating the test utilizing a two (2) minute slide rotation period. Reaction times longer than two minutes might cause false positive results due to a drying effect.
- Drugs such as hydralazine, isoniazid, procainamide and a number of anticonvulsant drugs can induce an SLE syndrome.
- In accord with all diagnostic methods, a final diagnosis should not be made on the result of a single test, but should be based on a correlation of test results with other clinical findings.

REFERENCES



















- Christian CL, Mendez-Bryan R, Larson DL. 1958. *Proc Exp Biol Med*, **98**:820-823.
- Friou GJ, Finch SC, Detre KD. 1958. *J Immunol*, **80**:324-329.
- Hargraves MM, Richmond H, Morton R. 1948. *Proc Mayo Clin*, **23**:25-28.
- Holman HR, Kunkel HG. 1957. *Science*, **126**:163.
- Miescher PA, Strassel R. 1957. *Vox Sang*, **2**:283-287.
- Miescher PA, Rothfield N, Miescher A. 1966. *Lupus Erythematosus*, EL Dubois, Ed., Blakiston Co., New York.

- Rothfield NF, Phythyon JJ, McEwan C., Miescher P. 1961. *Arth Rheum*, **4**:223-229.

 **ATLAS Medical GmbH**
Ludwig-Erhard Ring 3
15827 Blankenfelde-Mahlow
Germany
Tel: +49 - 33708 – 3550 30
Email: Info@atlas-medical.com
Website: www.atlas-medical.com

PP12339A01

Rev B (22.06.2023)

	Catalogue Number		Temperature limit
	In Vitro diagnostic medical device		Caution
	Contains sufficient for <n> tests and Relative size		Consult instructions for use (IFU)
	Batch code		Manufacturer
	Fragile, handle with care		Use-by date
	Manufacturer fax number		Do not use if package is damaged
	Manufacturer telephone number		Date of Manufacture
	Keep away from sunlight		Keep dry
	Positive control		Negative control

Atlas D-Dimer Latex Kit

IVD For In Vitro Diagnostic Use Only.

2°C ↑ 8°C
Store at 2°C to 8°C.

INTENDED USE

Atlas D-Dimer Latex Test is intended for the rapid qualitative or semi-quantitative evaluation of circulating derivatives of cross-linked fibrin degradation products (XL-FDP) in human plasma.

INTRODUCTION

During blood coagulation, fibrinogen is converted to fibrin by the activation of thrombin. The resulting fibrin monomers polymerize to form a soluble gel of non-cross-linked fibrin. This fibrin gel is then converted to cross-linked fibrin by thrombin activated Factor XIII to form an insoluble fibrin clot. Production of plasmin, the major clot-lysing enzyme, is triggered when a fibrin clot is formed. Fibrinogen and fibrin are both cleaved by the fibrinolytic enzyme plasmin to yield degradation products, but only degradation products from cross-linked fibrin contain D-Dimer. Therefore, cross-linked fibrin degradation products (XL-FDP) are a specific marker of fibrinolysis.

PRINCIPLE

Atlas D-Dimer Latex is a rapid agglutination assay utilizing latex beads coupled with a highly specific D-Dimer monoclonal antibody. XL-FDP present in a plasma sample bind to the coated latex beads, which results in visible agglutination occurring when the concentration of D-Dimer is above the threshold of detection of the assay.

MATERIALS

MATERIALS PROVIDED

- D-Dimer Latex Reagent: a 0.83% suspension of latex particles coated with murine anti-D-Dimer monoclonal antibody, 10mg/mL BSA and 0.1% sodium azide.
- D-Dimer Positive Control: a solution containing purified human D-Dimer fragment, 5mg/mL BSA and 0.1% sodium azide.
- D-Dimer Negative Control: a buffer solution containing 5mg/mL BSA and 0.1% sodium azide.
- Dilution Buffer
- Reaction slide
- Stirring Sticks
- Instructions for Use

MATERIALS NEEDED BUT NOT PROVIDED

- Precision pipettes and tips - 20 µL and 100 µL
- Plastic test tubes and rack
- Stopwatch or timing device

- Disposable gloves
- Tissue (for wiping dropper bottle tips)

PRECAUTIONS

- For In Vitro Diagnostic Use Only.
- Harmful if swallowed. Avoid contact with skin and eyes. Do not empty into drains.
- Wear suitable protective clothing.
- CAUTION: All reagents in Atlas D-Dimer Latex Kit contain sodium azide (0.1%) as preservative. Do not ingest or allow to contact skin or mucous membranes. Sodium azide may form explosive azides in metal plumbing. Use proper disposal procedures.
- CAUTION: The Positive Control in Atlas D-Dimer Latex Kit contains components of human origin. Each individual blood donation intended for the production of this reagent is tested for HBsAg, anti-HCV, anti-HIV1 and anti-HIV2. Only donations with negative findings are employed. As complete absence of infectious agents can never be assured, all materials derived from human blood should be treated as potentially infectious and handled with due care following the precautions recommended for biohazardous material.

STORAGE AND STABILITY

- Store at 2°C to 8°C.
- DO NOT FREEZE.
- Stability: Refer to outer package and vial labels for expiration date.
- Indication of Reagent Deterioration
Reagent deterioration is indicated by failure of the Latex Reagent to agglutinate with the Positive Control, agglutination with the Negative Control, or evidence of microbial contamination.

SPECIMEN COLLECTION AND PREPARATION

Plasma prepared from whole blood anticoagulated with sodium citrate is recommended. The use of EDTA and heparin will result in an increased level of false positive reactions. After separation of the plasma by centrifugation (1500g for 15 minutes at 4°C - 10°C), specimens may be tested directly for the presence of XL-FDP. Defibrination of the plasma is not recommended.
Plasma storage/stability: - 20°C: 2 weeks
Thaw frozen specimens rapidly at 37°C and centrifuge before testing.

PROCEDURE

- Equilibrate reagents to room temperature (20°C to 25°C) before use.
- Latex Reagent should be mixed by inversion immediately prior to use.

Qualitative Method

1. Bring reagents and specimens to room temperature before use.
2. Place 20 µL of the reagent within a well on a reaction slide. **AVOID** touching the surface of the Reaction slide
3. Accurately pipette 20 µL of undiluted plasma or of control solution inside the same well next to the drop of Latex Reagent.
4. Mix the Latex Reagent and sample with a stirrer until the Latex is uniformly distributed.

5. Rock the reaction slide gently by hand for exactly 3 minutes.
6. At exactly 3 minutes, check for agglutination under a strong light source.

NOTE

If test reading is delayed beyond 3 minutes, the latex suspension may dry out **giving a false agglutination pattern. If this is suspected, the specimen must be retested.**

Semi quantitative Method

1. Prepare serial dilutions of the test plasma with Buffer as follows:
1:2 dilution 100 µL plasma plus 100 µL Buffer solution
1:4 dilution 100 µL 1:2 dilution plus 100 µL Buffer solution
1:8 dilution 100 µL 1:4 dilution plus 100 µL Buffer solution
2. Test each dilution as described in the qualitative method.

QUALITY CONTROL

- It is recommended that both Positive and Negative Controls be included in each batch of tests to ensure proper functioning of the system. Control solutions should be tested by the same procedures as patient samples.
- D-Dimer Positive Control consists of a solution of human D-Dimer at a level of approximately ≥ 0.80 mg/L (≥ 800 ng/mL).

RESULTS

A. Qualitative Assay

For the qualitative assay protocol, the following pattern of results should be obtained:

Undiluted Plasma D-Dimer (XL-FDP) concentration

Negative Less than 0.20 mg/L (200ng/mL)
Positive Greater than 0.20 mg/L (200ng/mL)

Note: All values in mg/L (ng/mL) are approximate

B. Semiquantitative Assay

Approximate levels of XL-FDP, containing the D-Dimer domain, for specimen dilutions are shown in Table 1. As with all semiquantitative tests, some variability in dose-response can be expected.

Approximate Range of D-Dimer (XL-FDP) mg/L (ng/ml)	Sample Dilution			
	Undil.	1:2	1:4	1:8
< 0.2 (< 200)	-	-	-	-
0.2 – 0.4 (200 – 400)	+	-	-	-
0.4 – 0.8 (400 – 800)	+	+	-	-
0.8 – 1.6 (800 – 1600)	+	+	+	-
1.6 – 3.2* (1600 – 3200*)	+	+	+	+

“+” = agglutination, “-” = no agglutination

* Levels of XL-FDP greater than 3.20 mg/L (3200 ng/mL) can be estimated by further dilutions beyond 1:8.

EXPECTED VALUES

A positive result, indicating active fibrinolysis, should be obtained with D-Dimer Latex Test when XL-FDP (D-Dimer) levels are at or

greater than approximately 0.20 mg/L (200ng/mL). Plasma specimens from normal subjects are expected to give negative results because their plasma XL-FDP concentrations are typically less than 0.20 mg/L (200ng/mL). Due to many variables that may affect results, each laboratory should establish its own normal range.

Elevated levels of XL-FDP (containing the D-Dimer domain) have been demonstrated in patients by a combination of immunoprecipitation and gel electrophoresis techniques. Monoclonal antibodies allow the specific detection of the D-Dimer domain. Monoclonal antibody based D-Dimer assay is of diagnostic value in disseminated intravascular coagulation (DIC) and acute vascular diseases, including pulmonary embolism (PE) and deep venous thrombosis (DVT), conditions that are difficult to detect reliably by clinical examination.

The amount of XL-FDP detected in a specimen will depend on several interrelated factors in vivo, such as the severity of the thrombotic episode, the rate of cross linked fibrin formation, and the time elapsed after the thrombotic event until blood is drawn from the patient.

Elevated levels of XL-FDP as an indication of reactive fibrinolysis have also been reported in surgery, trauma, sickle cell disease, liver disease, severe infection, sepsis, inflammation, and malignancy. D-Dimer levels also rise during normal pregnancy but very high levels are associated with complications.

LIMITATIONS

Clinical diagnosis should not be based on the result of D-Dimer Latex alone. Clinical signs and other relevant test information should be included in the diagnostic decision.

SPECIFIC PERFORMANCE CHARACTERISTICS

- Plasma from one hundred and seventy (170) apparently healthy, voluntary blood donors was tested using Atlas D-Dimer Latex. A negative result was obtained for one hundred and sixty-two (162) of the samples. This equates to a specificity of 95.3% (162/170).
- One hundred and forty-five (145) plasma samples from patients judged to be suffering from, or having a high probability for thrombotic episode, were tested by Atlas D-Dimer Latex and another agglutination reference method. The correlation coefficient was $r=0.94$ and the regression equation was $y=1.19x$.
- Intra-assay (within run) reproducibility was determined for 10 replicates of 3 plasma samples that contained different levels of XL-FDP. The results were equivalent for all replicates.
- Inter-assay (run-to-run) reproducibility was determined using 10 plasma samples with XL-FDP titers ranging from 1 to 16. In 10 runs, the replicates of these specimens did not vary by more than one titer.
- In an anticoagulant study of 50 parallel citrated, EDTA and heparin plasma samples, the correlation between the titers obtained with Atlas D-Dimer Latex and the expected titers (based on ELISA XL-FDP values) was $r = 0.91$ for citrated samples, $r = 0.73$ for EDTA samples and $r = 0.78$ for heparin samples. Citrate is the anticoagulant of choice.
- Atlas D-Dimer Latex does not cross-react with fibrinogen, factor XIIIa cross-linked fibrinogen, or fibrinogen degradation products.

- The interference due to presence of rheumatoid factor (RF): in a study of samples from patients with rheumatoid arthritis, 17 were found to agglutinate with D-Dimer latex. In all 17 samples, the agglutination could be inhibited by the addition of the D-Dimer specific monoclonal antibody DD3B6/22, but not with a non-specific monoclonal antibody of the same subgroup, IgG3K. This suggests that D-Dimer latex is insensitive to rheumatoid factor disturbances.
- No assay interference was demonstrated with Atlas D-Dimer Latex with spiked specimens containing potential interfering substances at the following concentrations:
 - Bilirubin 0.2 mg/mL
 - Hemoglobin 5.0 mg/mL
 - Lipids (triglycerides) 30 mg/mL
 - Protein (gamma globulin) 0.06 g/mL

REFERENCES

1. Gaffney, P.J. Distinction between Fibrinogen and Fibrin Degradation Products in Plasma. Clin. Chim. Acta. 65 (1): 109-115; 1975.
2. Lane, D.A. et al. Characterisation of Serum Fibrinogen and Fibrin Fragments Produced During Disseminated Intravascular Coagulation. Br. J. Haematol. 40 (4): 609-615; 1978.
3. Whitaker, A.N. et al. Identification of D-Dimer-E complex in Disseminated Intravascular Coagulation. Thromb. Res. 18 (3-4): 453-459; 1980.
4. NCCLS Publication H21-A3 - Collection, Transport, and Processing of Blood Specimens for Coagulation Testing and General Performance of Coagulation Assays; Approved Guideline Third Edition; 1998.
5. Graeff, H. et al. Detection and Relevance of Crosslinked Fibrin Derivatives in Blood. Semin. Thromb. Hemost. 8 (1): 57-68; 1982.
6. Yoshioka, K. et al. Distinction between Fibrinogen and Fibrin Products Produced during Disseminated Intravascular Coagulation in Childhood. Eur. J. Pediatr. 138 (1): 46-48; 1982.
7. Rylatt, D.B. et al. An Immunoassay for Human D-Dimer using Monoclonal Antibodies. Thromb. Res. 31 (6): 767-778; 1983.
8. Elms, M.J. et al. Rapid Detection of Cross-Linked Fibrin Degradation Products in Plasma using Monoclonal Antibody-Coated Latex Particles. Am. J. Clin. Pathol. 85 (3): 360-364; 1986.
9. Whitaker, A.N. et al. Measurement of Cross-Linked Fibrin Derivatives in Plasma: an Immunoassay using Monoclonal Antibodies. J. Clin. Pathol. 37 (8): 882-887; 1984.
10. Hunt, F.A. et al. Serum Crosslinked Fibrin (XDP) and Fibrinogen/Fibrin Degradation Products (FDP) in Disorders Associated with Activation of the Coagulation or Fibrinolytic Systems. Br. J. Haematol. 60 (4): 715-722; 1985.
11. Smith, R.T. et al. Fibrin Degradation Products in the Postoperative Period. Evaluation of a New Latex Agglutination Method. Am. J. Clin. Pathol. 60 (5): 644-647; 1973.
12. Nolan, T.E. et al. Maternal Plasma D-Dimer Levels in Normal and Complicated Pregnancies. Obstet. Gynecol. 81 (2): 235-238, 1993.



ATLAS Medical

Unit 4, William James House

Cowley Rd, Cambridge, CB4 0WX, UK

Tel: ++44 (0) 1223 858 910

Fax: ++44 (0) 1223 858 524

PPI139A01

Rev E (03.03.2016)

REF	Catalogue Number		Store at
IVD	For In-Vitro Diagnostic use		Caution
	Number of tests in the pack		Read product insert before use
LOT	Lot (batch) number		Manufacturer
	Fragile, handle with care		Expiry date
	Manufacturer fax number		Do not use if package is damaged
	Manufacturer telephone number		



Add: No.9 Bofu Road, Luhe District, Nanjing, 211505, China
Tel: 86-25-68568508 Email: overseas@geteincom.cn Web: www.bio-GP.com.cn

Document No.: GP-GMSQ-2022-110

Letter of Authorization

To whom it may concern,

We, Getein Biotech, Inc. (No.9 BoFu Road, Luhe District, Nanjing, 211505, China), hereby authorize Sanmedico SRL. as our official distributor for registering, promoting, selling, distributing, taking part in tenders, maintaining & after sale technical services of under-mentioned product in the territory of Moldova:

Sanmedico SRL will comply with the laws and regulations of the countries and regions where they are located in and where they are selling mentioned product to, otherwise, the risks and losses arising therefrom shall be undertaken by Sanmedico SRL

This authorization starts from Jan 1, 2022 and will be valid to December 31 2023

Getein Biotech, Inc. has the right to terminate the authorization before validity and will inform Sanmedico SRL with 10 days in advance.

Getein Biotech, Inc.

Name: Steven Zhou

Position: Overseas Sales Director

基蛋生物科技股份有限公司
GETEIN BIOTECH, INC.

A handwritten signature in black ink that reads 'Steven Zhou'.



Declaration of Conformity



according to Directive 98/79/EC, on in vitro diagnostic medical devices

Maker (Name, Address)	Getein Biotech, Inc. No. 9 Bofu Road, Luhe District, Nanjing, 211505, China	
Authorized Representative (Name, Address)	Lotus NL B.V. Koningin Julianaplein 10, 1e Verd, 2595AA, The Hague, Netherlands.	
Medical device	Description :	FIA8000 Quantitative Immunoassay Analyzer FIA8600 Quantitative Immunoassay Analyzer Cardiac Troponin I Fast Test Kit One Step Test for cTnI (Colloidal Gold) cTnI Rapid Test (Colloidal Gold Assay) One Step Test for NT-proBNP (Colloidal Gold) One Step Test for NT-proBNP/cTnI (Colloidal Gold) One Step Test for CK-MB/cTnI/Myo (Colloidal Gold) One Step Test for hs-CRP+CRP (Colloidal Gold) One Step Test for D-Dimer (Colloidal Gold) One Step Test for PCT (Colloidal Gold) One Step Test for β 2-MG (Colloidal Gold) One Step Test for mAlb (Colloidal Gold) One Step Test for NGAL (Colloidal Gold) One Step Test for CysC (Colloidal Gold) One Step Test for HCG+ β (Colloidal Gold) One Step Test for HbA1c (Colloidal Gold) One Step Test for PCT/CRP (Colloidal Gold) One Step Test for CK-MB/cTnI/H-FABP (Colloidal Gold) One Step Test for H-FABP (Colloidal Gold) One Step Test for CK-MB/cTnI (Colloidal Gold) One Step Test for CK-MB (Colloidal Gold) One Step Test for TSH (Colloidal Gold) One Step Test for T4/T3 (Colloidal Gold) One Step Test for T3 (Colloidal Gold) One Step Test for T4 (Colloidal Gold) One Step Test for 25-OH-VD (Colloidal Gold) One Step Test for FOB (Colloidal Gold) One Step Test for <i>H. pylori</i> (Colloidal Gold) One Step Test for SAA (Colloidal Gold) Getein1100 Immunofluorescence Quantitative Analyzer Getein1600 Immunofluorescence Quantitative Analyzer Getein1180 Immunofluorescence Quantitative Analyzer Getein1200 Immunofluorescence Quantitative Analyzer Cardiac Troponin I Fast Test Kit (Immunofluorescence Assay) NT-proBNP Fast Test Kit (Immunofluorescence Assay) hs-CRP+CRP Fast Test Kit (Immunofluorescence Assay) NT-proBNP/cTnI Fast Test Kit (Immunofluorescence Assay) CK-MB/cTnI/Myo Fast Test Kit (Immunofluorescence Assay) D-Dimer Fast Test Kit (Immunofluorescence Assay)



		<p>PCT Fast Test Kit (Immunofluorescence Assay) β2-MG Fast Test Kit (Immunofluorescence Assay) mAlb Fast Test Kit (Immunofluorescence Assay) NGAL Fast Test Kit (Immunofluorescence Assay) CysC Fast Test Kit (Immunofluorescence Assay) CK-MB Fast Test Kit (Immunofluorescence Assay) CK-MB/cTnl Fast Test Kit (Immunofluorescence Assay) HCG+β Fast Test Kit (Immunofluorescence Assay) HbA1c Fast Test Kit (Immunofluorescence Assay) PCT/CRP Fast Test Kit (Immunofluorescence Assay) CK-MB/cTnl/H-FABP Fast Test Kit (Immunofluorescence Assay) H-FABP Fast Test Kit (Immunofluorescence Assay) 25-OH-VD Fast Test Kit (Immunofluorescence Assay) TSH Fast Test Kit (Immunofluorescence Assay) T3 Fast Test Kit (Immunofluorescence Assay) T4 Fast Test Kit (Immunofluorescence Assay) 25-OH-VD Fast Test Kit (Immunofluorescence Assay) FOB Fast Test Kit (Immunofluorescence Assay) <i>H. pylori</i> Fast Test Kit (Immunofluorescence Assay) SAA Fast Test Kit (Immunofluorescence Assay) LH Fast Test Kit (Immunofluorescence Assay) FSH Fast Test Kit (Immunofluorescence Assay) AMH Fast Test Kit (Immunofluorescence Assay) PRL Fast Test Kit (Immunofluorescence Assay) CK-MB Control cTnl Control Myo Control NT-proBNP Control D-Dimer Control CRP Control PCT Control β2-MG Control mAlb Control NGAL Control CysC Control H-FABP Control HbA1c Control HCG+β Control CK-MB/cTnl/Myo Control CK-MB/cTnl Control NT-proBNP/cTnl Control TSH Control T4/T3 Control T3 Control T4 Control</p>	
	Classification of products according to directive	:	Others
	Batch/serial No. Type, production term (if applicable)	:	



Applicable coordination standards:	EN ISO 14971:2012	EN ISO 23640:2015	EN ISO 13485:2016
	EN 13612:2002	EN ISO15223-1:2012	EN ISO 18113-2:2011
	EN 1041:2008	EN ISO 18113-1:2011	EN ISO 18113-3:2011
	IEC 61010-1:2010	IEC 61010-2-081:2015	IEC 61010-2-101:2015
	IEC 61326-1:2013	IEC 61326-2-2:2013	

Signatory representative declares herein the above mentioned device meets the basic requirements of the European Parliament and the Council's in vitro diagnostic medical devices directive: 98/79/EC Annex III. This declaration of conformity is based on European Parliament and the Council's 98/79/EC directive Annex III. The compiled technical file and quality system document according to 98/79/EC directive Annex III are testified and the quality system certificate has issued by TÜV Rheinland (Shanghai) Co., Ltd.

General Manager: Enben Su

Nha Trang, 20th, Jul, 2019
(place and date of issue)

_____ 
(name and signature or equivalent marking of authorized person)




Certificate of Registration

QUALITY MANAGEMENT SYSTEM - ISO 13485:2016

This is to certify that: **Getein Biotech, Inc.**
No.9 Bofu Road
Luhe District
Nanjing
Jiangsu
211505
China

基蛋生物科技股份有限公司
中国
江苏省
南京市
六合区
沿江工业开发区
博富路9号
邮编: 211505

Holds Certificate No: **MD 728432**

and operates a Quality Management System which complies with the requirements of ISO 13485:2016 for the following scope:

Please see scope page.

For and on behalf of BSI:

Graeme Tunbridge, Senior Vice President Medical Devices

Original Registration Date: 2020-05-29

Latest Revision Date: 2023-04-26

Effective Date: 2023-07-26

Expiry Date: 2026-07-25

Page: 1 of 3



...making excellence a habit.™

Certificate No: **MD 728432**

Registered Scope:

Design & Development, Manufacture and Distribution of Chemiluminescence Immunoassay, Biochemistry Assay, Point of Care Assay (including Colloidal Gold Assay, Immunofluorescence Assay, Dry Chemistry Assay), PCR Assay and Colloidal Gold self-testing Assay to detect infectious disease. Design & Development, Manufacture and Distribution of Analyzers in use of Chemiluminescence Immunoassay, Biochemistry Assay, Point of Care Assay (including Colloidal Gold Assay, Immunofluorescence Assay, Dry Chemistry Assay), PCR Assay to detect infectious disease, Immunofluorescence self-testing Assay to detect dyslipidemia disease, Blood Coagulation Assay to detect thrombotic disease.

研发, 生产和销售化学发光法试剂, 生化试剂, 即时诊断 (包括胶体金法, 免疫荧光法, 干式化学法) 试剂, 传染病相关PCR分子诊断试剂和胶体金自测试剂。 研发, 生产和销售用于化学发光法试剂, 生化试剂, 即时诊断 (包括胶体金法, 免疫荧光法, 干式化学法) 试剂, 传染病相关PCR分子诊断试剂, 血脂异常疾病相关免疫荧光自测试剂, 血栓疾病相关血凝试剂配套使用的分析仪。



Original Registration Date: 2020-05-29

Latest Revision Date: 2023-04-26

Effective Date: 2023-07-26

Expiry Date: 2026-07-25

Page: 2 of 3

This certificate was issued electronically and remains the property of BSI and is bound by the conditions of contract.

An electronic certificate can be authenticated [online](#).

Printed copies can be validated at www.bsi-global.com/ClientDirectory or telephone +86 10 8507 3000.

Information and Contact: BSI, John M. Keynesplein 9, 1066 EP Amsterdam The Netherlands. Tel: +31 (0) 20 3460 780

BSI Group The Netherlands B.V., registered in the Netherlands under number 33264284, at John M. Keynesplein 9, 1066 EP Amsterdam, The Netherlands

A Member of the BSI Group of Companies.

Certificate No: **MD 728432**

Location

Getein Biotech, Inc.
No.9 Bofu Road
Luhe District
Nanjing
Jiangsu
211505
China
基蛋生物科技股份有限公司
中国
江苏省
南京市
六合区
沿江工业开发区
博富路9号
邮编: 211505

Registered Activities

Design & Development, Manufacture and Distribution of Chemiluminescence Immunoassay, Biochemistry Assay, Point of Care Assay (including Colloidal Gold Assay, Immunofluorescence Assay, Dry Chemistry Assay), PCR Assay and Colloidal Gold self-testing Assay to detect infectious disease. Design & Development, Manufacture and Distribution of Analyzers in use of Chemiluminescence Immunoassay, Biochemistry Assay, Point of Care Assay (including Colloidal Gold Assay, Immunofluorescence Assay, Dry Chemistry Assay), PCR Assay to detect infectious disease, Immunofluorescence self-testing Assay to detect dyslipidemia disease, Blood Coagulation Assay to detect thrombotic disease.
研发, 生产和销售化学发光法试剂, 生化试剂, 即时诊断 (包括胶体金法, 免疫荧光法, 干式化学法) 试剂, 传染病相关PCR分子诊断试剂和胶体金自测试剂。 研发, 生产和销售用于化学发光法试剂, 生化试剂, 即时诊断 (包括胶体金法, 免疫荧光法, 干式化学法) 试剂, 传染病相关PCR分子诊断试剂, 血脂异常疾病相关免疫荧光自测试剂, 血栓疾病相关血凝试剂配套使用的分析仪。

Getein Biotech, Inc.
No. 6 KeFeng Road
Jiangbei New District
Nanjing
Jiangsu
211505
China
基蛋生物科技股份有限公司
中国
江苏省
南京
江北新区
科丰路6号
邮编: 211505

Manufacture of Chemiluminescence Immunoassay, Biochemistry Assay, Point of Care Assay (including Colloidal Gold Assay, Immunofluorescence Assay, Dry Chemistry Assay), Colloidal Gold self-testing Assay to detect infectious disease. Manufacture of Analyzers in use of Chemiluminescence Immunoassay, Biochemistry Assay, Point of Care Assay (including Colloidal Gold Assay, Immunofluorescence Assay, Dry Chemistry Assay), PCR Assay to detect infectious disease, Immunofluorescence self-testing Assay to detect dyslipidemia disease, Blood Coagulation Assay to detect thrombotic disease.
生产化学发光法试剂, 生化试剂, 即时诊断 (包括胶体金法, 免疫荧光法, 干式化学法) 试剂和传染病相关胶体金自测试剂。 生产用于化学发光法试剂, 生化试剂, 即时诊断 (包括胶体金法, 免疫荧光法, 干式化学法) 试剂, 传染病相关PCR分子诊断试剂, 血脂异常疾病相关免疫荧光自测试剂, 血栓疾病相关血凝试剂配套使用的分析仪。

Original Registration Date: 2020-05-29

Effective Date: 2023-07-26

Latest Revision Date: 2023-04-26

Expiry Date: 2026-07-25

Page: 3 of 3

This certificate was issued electronically and remains the property of BSI and is bound by the conditions of contract.

An electronic certificate can be authenticated [online](#).

Printed copies can be validated at www.bsi-global.com/ClientDirectory or telephone +86 10 8507 3000.

Information and Contact: BSI, John M. Keynesplein 9, 1066 EP Amsterdam The Netherlands. Tel: +31 (0) 20 3460 780

BSI Group The Netherlands B.V., registered in the Netherlands under number 33264284, at John M. Keynesplein 9, 1066 EP Amsterdam, The Netherlands

A Member of the BSI Group of Companies.



Cardiac Troponin I Fast Test Kit

User Manual

Cat.# CG2001

INTENDED USE

Cardiac Troponin I Fast Test Kit is intended for *in vitro* qualitative and semi-quantitative determination of cardiac Troponin I (cTnI) in serum, plasma or whole blood. This test is used as an aid in the diagnosis of myocardial injury such as Acute Myocardial Infarction (AMI), Unstable Angina, Acute Myocarditis and Acute Coronary Syndrome (ACS).

SUMMARY

Troponin, a molecular complex that is bound to the thin filament (actin) of striated muscle fibers, acts with intracellular calcium to control the interaction of the thin filament with the thick filament (myosin), thus regulating muscle contraction. Troponin consists of three subunits: T, which connects the troponin complex and tropomyosin (another cardiac muscle regulatory protein); I, which prevents muscle contraction in the absence of calcium; and C, which binds calcium. Cardiac Troponin I (MW 22.5 kDa) and the two skeletal muscle isoforms of Troponin I have considerable amino acid sequence homology, but cTnI contains an additional N-terminal sequence and is highly specific for myocardium.

Clinical studies have demonstrated the release of cTnI into the blood stream within hours following acute myocardial infarctions (AMI) or ischemic damage. Elevated levels of cTnI are detectable in blood within 4 to 6 hours after the onset of chest pain, reaching peak concentrations in approximately 8 to 28 hours, and remain elevated for 3 to 10 days following AMI. Due to the high myocardial specificity and the long duration of elevation, cTnI has become an important marker in the diagnosis and

evaluation of patients suspected of having an AMI.

The current guideline of The Joint European Society of Cardiology/ American College of Cardiology Committee support the use of cTnI as a preferred marker of myocardial injury. Several major studies have shown that cTnI is also a predictor of cardiac risk in patients with unstable angina. The American College of Cardiology and the American Heart Association's current guidelines recommend using troponin results when making treatment decisions regarding unstable angina and non-ST segment elevation MI (NSTEMI).

PRINCIPLE

The test uses an anti-human cTnI monoclonal antibody conjugated with colloidal gold and another anti-human cTnI monoclonal antibody coated on the test line. After the sample has been applied to the test strip, the gold-labelled anti-human cTnI monoclonal antibody binds with the cTnI in sample and forms a marked antigen-antibody complex. This complex moves to the test card detection zone by capillary action. Then marked antigen-antibody complex is captured on the test line by the anti-human cTnI monoclonal antibody resulting in a purplish red streak appears on the test line. The color intensity of the test line increases in proportion to the amount of cTnI in sample.

CONTENTS

A kit contains:

- | | |
|---|----|
| 1. Getein cTnI test card in a sealed pouch with desiccant | 25 |
| 2. Disposable pipet | 25 |
| 3. User manual | 1 |
| 4. Standard colorimetric card | 1 |
| 5. Whole blood buffer | 1 |

A test card consists of:

A plastic shell and a reagent strip which is composed of a sample pad, a colloid gold pad (coated with gold-labelled anti-human cTnI monoclonal antibody), nitrocellulose membrane (the test line is coated with anti-human cTnI monoclonal antibody, and the control line is coated with rabbit anti-mouse IgG antibody), absorbent paper and liner.

Whole blood buffer composition:

Phosphate buffered saline, proteins, detergent, preservative, stabilizer.

Note: Do not mix or interchange different batches of kits.

STORAGE AND STABILITY

Store the test card at 4~30°C with a valid period of 24 months. Use the test card within 1 hour once the foil pouch is opened. Store the whole blood buffer at 0~30°C with a valid period of 24 months. Store the whole blood buffer at 2~8°C for better results.

PRECAUTIONS

1. For *in vitro* diagnostic use only.
2. For professional use only.
3. Do not use the kit beyond the expiration date.
4. Do not use the test card if the foil pouch is damaged.
5. Do not open pouches until ready to perform the test.
6. Do not reuse the test card.
7. Do not reuse the pipet.
8. Handle all specimens as potentially infectious. Proper handling and disposal methods should be followed in accordance with local regulations.
9. Carefully read and follow user manual to ensure proper test performance.

SPECIMEN COLLECTION AND PREPARATION

1. This test can be used for **serum, plasma or whole blood samples. Heparin, EDTA or sodium citrate** should be used as the anticoagulant for plasma and whole blood. Samples should be free of hemolysis.
2. Suggest using serum or plasma for better results.
3. Serum or plasma can be used directly. For whole blood sample, whole blood buffer must be added before testing.
4. If testing will be delayed, serum and plasma samples may be stored up to 7 days at 2~8°C or stored at -20°C for 6 months before testing (whole blood sample may be stored up to 3 days at 2~8°C).

- Refrigerated or frozen sample should reach room temperature and be homogeneous before testing. Avoid multiple freeze-thaw cycles.
- Do not use heat-inactivated samples.
- SAMPLE VOLUME: **80 µl**.

TEST PROCEDURE

- Collect specimens according to user manual.
- Test card, sample and reagent should be brought to room temperature before testing.
- Remove the test card from the sealed pouch immediately before use. Label the test card with patient or control identification.
- Put the test card on a clean table, horizontally placed.
- Using sample transfer pipette, deliver **80 µl** of sample (or 3 drops of sample when using disposable pipet) into the sample port on the test card (for whole blood sample, one drop of whole blood buffer must be added after loading 80 µl sample on the test card).
- Read the results visually in 15 minutes.** For semi-quantitative interpretation of results, please refer to the standard colorimetric card.

TEST RESULTS

Negative: A single purplish red band appears at the control area (C) without any other band at test line is a valid negative result, indicating the concentration of cTnI in the sample is below the cut-off value.

Positive: A single purplish red band appears at the control area (C) and a purplish red colored band appears in test line is a valid positive result. The intensity of the purplish red color in the test line helps to read the semi-quantitative result visually according to the standard colorimetric card:

Color intensity	Reference Concentration (ng/ml)
—	<0.3
+—	0.3~1
+	1~5
++	5~15
+++	15~30
++++	30~50
++++	>50

Invalid: If no colored band appears in the control area (C) in 15 minutes, the test result is invalid. The test should be repeated and if the same situation happened again, please stop using this batch of products and contact your supplier.

EXPECTED VALUE

The expected normal value for Troponin I was determined by testing samples from 500 apparently healthy individuals. The 99th percentile of the concentration for cTnI is 0.3 ng/ml, (The probability that value of a normal person below 0.3 ng/ml is 99%). cTnI concentration less than 0.3 ng/ml can be estimated as normal.

It is recommended that each laboratory establish its own expected values for the population it serves.

LIMITATIONS

As with all diagnostic tests, a definitive clinical diagnosis should not be made based on the result of a single test. The test results should be interpreted considering all other test results and clinical information such as clinical signs and symptoms.

REFERENCES

- Mauro Pantaghini; Undefined International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). Scientific Division Committee on Standardization of Markers of Cardiac Damage. Clin Chem Lab Med, 1998, 36:887~893.
- Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Manage 2004).
- EN ISO 18113-1:2011 In vitro diagnostic medical devices - Information supplied by the manufacturer (labelling) - Part 1: Terms, definitions and general requirements.
- EN ISO 18113-2:2011 In vitro diagnostic medical devices - Information supplied by the manufacturer (labelling) - Part 2: In vitro diagnostic reagents for professional use (ISO18113-2:2011).

DESCRIPTION OF SYMBOLS USED

The following graphical symbols used in or found on Cardiac Troponin I Fast Test Kit are the most common ones appearing on medical devices and their packaging. They are explained in more details in the European Standard EN 980:2008 and International Standard ISO 15223 – 1: 2012.

Key to symbols used			
	Manufacturer		Expiration date
	Do not reuse		Date of manufacture
	Consult instructions for use	LOT	Batch code
	Temperature limitation	IVD	In vitro diagnostic medical device
	Sufficient for	EC REP	Authorized representative in the European Community
CE	CE mark		Do not use if package is damaged

Thank you for purchasing Cardiac Troponin I Fast Test Kit. Please read this user manual carefully before operating to ensure proper use.

Version: WCG01A-DX-S-02



Getein Biotech, Inc.
 Add: No.9 Bofu Road, Luhe District, Nanjing, 211505, China
 Tel: +86-25-68568508
 Fax: +86-25-68568500
 E-mail: tech@getein.com.cn
 overseas@getein.com.cn
 Website: www.bio-gp.com.cn